Our top pick for
Building a portfolio
Aeterna Zentaris Inc is a biotechnology business based in the US. Aeterna Zentaris shares (AEZS) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||USD$0.36|
|52-week range||USD$0.29 - USD$1.38|
|50-day moving average||USD$0.3785|
|200-day moving average||USD$0.4681|
|Wall St. target price||USD$4.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.748|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-15)||-43.75%|
|1 month (2020-12-23)||-12.20%|
|3 months (2020-10-23)||0.81%|
|6 months (2020-07-23)||-26.53%|
|1 year (2020-01-23)||-72.93%|
|2 years (2019-01-23)||-89.63%|
|3 years (2018-01-23)||2.4|
|5 years (2016-01-22)||3.06|
|Revenue TTM||USD$1.3 million|
|Gross profit TTM||USD$122,000|
|Return on assets TTM||-16.18%|
|Return on equity TTM||-74.3%|
|Market capitalisation||USD$24.3 million|
TTM: trailing 12 months
There are currently 1.9 million Aeterna Zentaris shares held short by investors – that's known as Aeterna Zentaris's "short interest". This figure is 28.1% up from 1.5 million last month.
There are a few different ways that this level of interest in shorting Aeterna Zentaris shares can be evaluated.
Aeterna Zentaris's "short interest ratio" (SIR) is the quantity of Aeterna Zentaris shares currently shorted divided by the average quantity of Aeterna Zentaris shares traded daily (recently around 3.8 million). Aeterna Zentaris's SIR currently stands at 0.5. In other words for every 100,000 Aeterna Zentaris shares traded daily on the market, roughly 500 shares are currently held short.
However Aeterna Zentaris's short interest can also be evaluated against the total number of Aeterna Zentaris shares, or, against the total number of tradable Aeterna Zentaris shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aeterna Zentaris's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Aeterna Zentaris shares in existence, roughly 30 shares are currently held short) or 0.0301% of the tradable shares (for every 100,000 tradable Aeterna Zentaris shares, roughly 30 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aeterna Zentaris.
Find out more about how you can short Aeterna Zentaris stock.
We're not expecting Aeterna Zentaris to pay a dividend over the next 12 months.
Aeterna Zentaris's shares were split on a 1:100 basis on 20 November 2015. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aeterna Zentaris shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Aeterna Zentaris shares which in turn could have impacted Aeterna Zentaris's share price.
Over the last 12 months, Aeterna Zentaris's shares have ranged in value from as little as $0.29 up to $1.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeterna Zentaris's is 2.4425. This would suggest that Aeterna Zentaris's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.